gstt.sthames.nhs.uk Although bladder function is thought to be unaffected in Duchenne muscular dystrophy, 46/88 boys interviewed had urinary problems. Nine underwent video urodynamics, showing in ...

Objective The relationship between functional dependence and quality of life (QOL) in Duchenne muscular dystrophy (DMD) patients and burden and QOL in caregivers is not clear. This study investigated ...

Video: Living Safely, but Still Living a Full Life with Duchenne Muscular Dystrophy —From being careful of small rugs in the house to adding a handrail to the stairs to the garage—these are ...

2 The current retrospective, US population-based, longitudinal study used surveillance data from the multi-site Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet ...

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of ...

Health Secretary Neil Gray has been furiously condemned for failing to ensure access to a new muscular dystrophy drug for desperate children. About 30 boys with a rare form of the killer disease ...

Duchenne muscular dystrophy (DMD), recognised by the World Health Organization (WHO) as a rare disease, is the most common form of childhood muscular dystrophy. It is a progressive genetic ...

Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy, affecting 1 in 3500-6000 boys. It is caused by changes in the dystrophin gene, located on the X chromosome, which results in ...

Cas12Max-based gene editing therapy for Duchenne muscular dystrophy, one of the most severe forms of the inherited muscular dystrophies that affects primarily boys. Huidagene Therapeutics and ...

Solve FSH, a venture philanthropic organization, has invested $3 million to support the development of Armatus Bio‘s microRNA-based therapy ARM-201 as a treatment for facioscapulohumeral muscular ...

Armatus Bio Inc.’s development of ARM-201, an AAV-delivered microRNA therapy for facioscapulohumeral muscular dystrophy (FSHD), has been boosted by a $3 million investment by Solve FSHD.

An oral presentation will focus on the treatment of Hemophilia A while new data in the poster session targets the treatment of Duchenne Muscular Dystrophy (DMD). Both presentations at ASGCT feature ...